Navigation Links
PDL BioPharma Announces First Quarter 2013 Financial Results
Date:5/9/2013

INCLINE VILLAGE, Nev., May 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Royalty revenues for the first quarter of 2013 increased 19 percent over the same period of 2012. Total revenues for the first quarter of 2013 were $91.8 million compared to $77.3 million for the same period in 2012. 

Royalty revenues for the first quarter of 2013 are based on fourth quarter 2012 product sales by PDL's licensees. The growth in royalty revenues was driven primarily by increased royalties from fourth quarter 2012 sales of Avastin®, Herceptin®, Lucentis®, Tysabri®, and Actemra®.  

General and administrative expenses for the first quarter of 2013 were $7.2 million compared with $6.9 million in the same period of 2012.

Net income for the first quarter of 2013 was $53.5 million or $0.36 per diluted share as compared with $40.2 million, or $0.29 per diluted share in the comparable quarter of 2012. The increase in net income is due to the 19 percent increase in royalty revenues and the resulting 33 percent increase in net income.

Net cash provided by operating activities in the first quarter of 2013 was $54.0 million compared with net cash provided by operating activities of $17.9 million for the first quarter of 2012.  At March 31, 2013, PDL had cash, cash equivalents and investments of $187.2 million, compared with $148.7 million at December 31, 2012.

Recent DevelopmentsStructured Financing and Royalty Transaction with Avinger
On April 18, 2013, PDL entered into a Credit Agreement wit
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
3. CeNeRx BioPharma Completes $4.85 Million Financing
4. PDL BioPharma Completes Regular Quarterly Dividend Payment
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
7. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
10. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Approval of Genasense in Relapsed/Refractory Patients, BERKELEY ... GNTA ) announced that the Company has completed ... Janet Woodcock, Acting,Director of the Center for Drug ... Administration (FDA). The appeal asks that CDER approve ...
... Cell,Genesys, Inc. (Nasdaq: CEGE ), today announced ... and Sharon E. Tetlow, senior,vice president and chief financial ... to the company,s third quarter financial results,that will be ... at 2:00 p.m. PT/ 5:00 p.m. ET. The ...
... Include World-Renowned RNase and RNA Researchers, SOMERSET, ... of ribonuclease (RNase) therapeutics will be the focus ... by Alfacell,Corporation (Nasdaq: ACEL ). Moderated ... officer, and David Sidransky, M.D., Alfacell,s scientific,advisory board ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... UT Southwestern neuroscience researchers have identified a gene that controls ... mice often used to study addiction and behavior patterns. ... , determines how mammals respond to cocaine, although it is ... or for addiction, said Dr. Joseph Takahashi , chair ...
... Department of Energy,s Brookhaven National Laboratory have identified a ... class of plant products with a wide range of ... source of flavors, fragrances, and pigments; some are of ... contribution to the construction of plant cell walls, (poly)phenols ...
... of superstars in the materials world. Already prized for ... identity, vanadium dioxide can now add muscle power to ... Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... from vanadium dioxide that for its size is a ...
Cached Biology News:UT Southwestern neuroscience researchers identify gene involved in response to cocaine 2Enlisting cells' protein recycling machinery to regulate plant products 2A micro-muscular breakthrough 2A micro-muscular breakthrough 3